RNA therapeutics are advancing rapidly, and the decisions made before a study begins can have a lasting impact on development. Choosing the right country, investigators, and study strategy can influence timelines, operational efficiency, and the quality of the data generated.
Join Novotech and guest experts for a discussion on why New Zealand is increasingly being selected for early-phase RNA clinical trials. Drawing on sponsor, investigator, and CRO perspectives, the panel will share practical insights into planning RNA studies, selecting the right sites, and establishing an efficient pathway into the clinic.
Whether you're preparing for a first-in-human study or evaluating options for your next development program, this webinar will provide practical considerations to help inform your early-phase strategy.
In this webinar, you'll learn
- What makes New Zealand well suited to early-phase RNA clinical trials
- Planning considerations that can help avoid common study start-up delays
- How experienced investigators and dedicated research sites support efficient trial delivery
- Factors to consider when selecting countries and sites for RNA development
- Practical perspectives from sponsors and clinical experts involved in RNA clinical research
Moderator: Rebecca Dean, Project Oversight Director, Novotech
Panelists:
- Prof. Ed Gane, University of Auckland/NZCR;
- James Hamilton, MD, MBA, Arrowhead Pharma;
- Carolyn Luscombe, PhD, Therapeutic Strategy Manager, Novotech;
- Sweta Kumar, Senior Consultant, Drug Development Consulting, Novotech